-
公开(公告)号:US20190249147A1
公开(公告)日:2019-08-15
申请号:US16310632
申请日:2017-06-20
CPC分类号: C12N5/0697 , C12N2501/11 , C12N2501/155 , C12N2501/33 , C12N2501/60 , C12N2502/081 , C12N2502/086 , C12N2503/04 , C12N2533/90 , G01N33/5058 , G01N33/54373
摘要: Compositions and methods are provided for biologically relevant in vitro screening of neural function, including determination of the effects of an agent on neural cells. The compositions of the invention useful in such screening methods include a neural co-culture system comprising human pluripotent stem cell (PSC)-derived neurons and human glial cells, which may be derived by culture methods allowing for rapid and robust development of highly mature neuronal activity, particularly spontaneous synchronous network bursts.
-
公开(公告)号:US20190194624A1
公开(公告)日:2019-06-27
申请号:US16310360
申请日:2017-06-16
发明人: Dhruv SAREEN , Loren A. ORNELAS , Clive SVENDSEN
CPC分类号: C12N5/0696 , C12N5/0018 , C12N2500/12 , C12N2500/38 , C12N2501/115 , C12N2501/2302 , C12N2501/2303 , C12N2501/2306 , C12N2501/33 , C12N2501/998 , C12N2506/11 , C12N2533/52
摘要: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
-
公开(公告)号:US20190194620A1
公开(公告)日:2019-06-27
申请号:US16288259
申请日:2019-02-28
发明人: James Palis , Samantha England , Ah Ram Kim
CPC分类号: C12N5/0641 , A61K35/18 , C12N2500/36 , C12N2500/90 , C12N2501/125 , C12N2501/14 , C12N2501/33 , C12N2501/39 , C12N2506/02 , C12N2510/00
摘要: The present invention provides a human cell population that can self-renew extensively and yet retain the capacity to differentiate into red blood cells (RBCs). These cells are referred to as extensively self-renewing erythroblasts (ESREs). The cells of the invention serve among other things as a renewable source of transfusable RBCs.
-
4.
公开(公告)号:US20190093083A1
公开(公告)日:2019-03-28
申请号:US16199681
申请日:2018-11-26
发明人: Xiaofang Xu , Jon Odorico , Erik Forsberg , Amber A. Mael
CPC分类号: C12N5/0676 , A61K9/1652 , A61K9/5036 , A61K35/39 , A61K35/545 , A61K45/06 , C12N2500/05 , C12N2500/22 , C12N2500/25 , C12N2500/38 , C12N2500/44 , C12N2500/90 , C12N2501/01 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/117 , C12N2501/155 , C12N2501/16 , C12N2501/33 , C12N2501/335 , C12N2501/385 , C12N2501/395 , C12N2501/40 , C12N2501/727 , C12N2501/91 , C12N2501/998 , C12N2501/999 , C12N2506/02 , C12N2506/45 , G01N33/507 , H05K999/99
摘要: Methods, kits, compositions, and systems are provided for culturing pluripotent stem cells to produce populations of cells comprising beta-like cells (e.g., pancreatic lineage, glucose-responsive, and/or insulin-producing). In particular, culture conditions are provided that result in the generation of beta-like cells from a starting culture of human pluripotent stem cells.
-
公开(公告)号:US10071050B2
公开(公告)日:2018-09-11
申请号:US15429493
申请日:2017-02-10
发明人: Yong Woo Cho , Ji Suk Choi , Eun Ji Kim , Hwa In Yoon , Jun Sung Kim
CPC分类号: A61K8/981 , A61K8/0216 , A61K8/31 , A61K8/342 , A61K8/345 , A61K8/361 , A61K8/41 , A61K8/585 , A61K8/8105 , A61K8/86 , A61K8/925 , A61K35/28 , A61K35/35 , A61K35/51 , A61K2800/70 , A61K2800/74 , A61K2800/805 , A61K2800/86 , A61P17/00 , A61P17/02 , A61P17/18 , A61Q19/00 , A61Q19/02 , A61Q19/08 , C12N5/0629 , C12N5/0653 , C12N5/0656 , C12N5/0667 , C12N2500/90 , C12N2501/135 , C12N2501/15 , C12N2501/22 , C12N2501/231 , C12N2501/25 , C12N2501/33 , C12N2501/355 , C12N2501/48 , C12N2501/50 , C12N2501/734 , C12N2502/1382 , C12N2506/1384
摘要: A cosmetic composition for skin whitening, wrinkle improvement or skin regeneration includes, as an active ingredient, exosomes derived from stem cells comprising proliferating stem cells.
-
公开(公告)号:US09896657B2
公开(公告)日:2018-02-20
申请号:US14823187
申请日:2015-08-11
发明人: Choun-Ki Joo , Hyun Soo Lee
IPC分类号: C12N15/00 , C12N5/0797 , A61K35/30
CPC分类号: C12N5/0623 , A61K35/30 , C12N5/062 , C12N2500/46 , C12N2500/84 , C12N2501/11 , C12N2501/155 , C12N2501/33 , C12N2501/39 , C12N2506/45
摘要: The present invention relates to a method of inducing differentiation of a stem cell into a corneal limbal stem cell, and a medium composition used therein. Further, the present invention relates to a pharmaceutical composition for treating corneal damage, including a corneal limbal stem cell differentiated using the above-described method as an active ingredient.
-
公开(公告)号:US20180042970A1
公开(公告)日:2018-02-15
申请号:US15694152
申请日:2017-09-01
CPC分类号: A61K35/44 , A61K9/0019 , A61K9/5063 , A61K35/28 , C12N5/0691 , C12N5/0697 , C12N2501/02 , C12N2501/115 , C12N2501/165 , C12N2501/33 , C12N2501/385 , C12N2501/39 , C12N2501/395 , C12N2501/81 , C12N2502/1352 , C12N2502/1358 , C12N2502/28 , C12N2539/00
摘要: Spheroid microtissues that can mimic native tissue-like structure and function, spheroid production methods that are high-throughput, suitable for efficient production, maintainable over long-term culture, and/or offer repeatable control over size distribution. Spheroids that have blood vessels, including spheroids with functional, blood-perfused vascular networks upon injection in vivo. Dissolvable hydrogel microwell arrays for high throughput parallel formation of spheroids in a single pipetting step and easy retrieval for downstream applications. A method to produce prevascularized microtissues in sufficient numbers to form a macrotissue in vivo for therapeutic purposes. This method is based on sacrificial release of dissolvable microwell templates, a novel and scalable strategy which enables gentle harvesting of microtissues with control over size and composition. The method forms microtissues containing endothelial cells and mesenchymal stem cells, which are co-cultured under dynamic conditions and self-organize into blood-vessel units.
-
公开(公告)号:US20170313986A1
公开(公告)日:2017-11-02
申请号:US15523260
申请日:2015-10-28
申请人: R BIO CO., LTD.
发明人: Jeong Chan RA , Sung Keun KANG , Sung-Min KIM , Mi Sook LEE , Jin Hwa LEE , Soon Ae KWON
IPC分类号: C12N5/0775
CPC分类号: C12N5/0667 , C12N2500/05 , C12N2500/14 , C12N2500/30 , C12N2500/32 , C12N2500/38 , C12N2500/84 , C12N2500/99 , C12N2501/115 , C12N2501/30 , C12N2501/33 , C12N2501/39
摘要: The present disclosure relates to a medium composition for culturing stem cells, and more specifically, to a medium composition for culturing mesenchymal stem cells, in which the medium composition includes a basic medium in which various quasi-completed mediums (DMEM, α-MEM, IMDM, F12, and DMEM/F12) are mixed, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factors (b-FGF), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone.According to the present disclosure, it is capable of improving proliferation ability and differentiation ability of the mesenchymal stem cells, and is capable of producing cell therapy products more economically using the mesenchymal stem cells by enabling the mesenchymal stem cells to be cultured at a low price compared to the existing culturing methods.
-
公开(公告)号:US09801977B2
公开(公告)日:2017-10-31
申请号:US14354545
申请日:2012-10-29
申请人: Vuk Savkovic , Christina Dieckmann , Jan-Christoph Simon , Michaela Schulz-Siegmund , Michael Hacker
发明人: Vuk Savkovic , Christina Dieckmann , Jan-Christoph Simon , Michaela Schulz-Siegmund , Michael Hacker
CPC分类号: A61L27/3834 , A61L27/3895 , A61L27/60 , C12N5/0626 , C12N2500/02 , C12N2500/38 , C12N2501/33 , C12N2501/81 , C12N2506/03 , C12N2533/40
摘要: The present invention relates to the field of biology and medicine, and more specifically, to the field of stem-cell biology, involving producing or generating melanocytes from stem-cells and precursors derived from human hair root. Additionally, the present invention relates to the materials and method for producing autografts, homografts or allografts comprising melanocytes in general, as well as the materials and methods for producing autografts, homografts and allografts comprising melanocytes for the treatment of diseases related to depigmentation of the skin and for the treatment of scars.
-
公开(公告)号:US20170304369A1
公开(公告)日:2017-10-26
申请号:US15517912
申请日:2015-10-08
发明人: Lay Teng ANG , Kyle M. LOH , Bing LIM
IPC分类号: A61K35/407 , C12N5/071 , C12N5/073 , G01N33/00 , C12N5/00
CPC分类号: A61K35/407 , C12N5/00 , C12N5/0603 , C12N5/067 , C12N5/0672 , C12N2500/38 , C12N2500/44 , C12N2501/00 , C12N2501/01 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/237 , C12N2501/33 , C12N2501/385 , C12N2501/39 , C12N2501/415 , C12N2501/42 , C12N2501/727 , C12N2506/02 , G01N33/00
摘要: The present disclosure provides methods and kits for the differentiation of stem cells into relevant liver cell lineages, as well as methods of using the relevant liver cell lineages in screening for a cellular response, a phenotype and in the treatment of a condition. In one embodiment, stem cells are first differentiated into cells of the definitive endoderm lineage, which are differentiated into posterior foregut (PFG) lineage cells by one or more of retinoic acid activators and/or one or more inhibitors of transforming growth factor-β (TGFβ). An additional embodiment provides a method for the differentiation of posterior foregut lineage cells into liver bud progenitors (LB) by one or more activators of TGFβ signalling, and/or one or more modulators of Wnt signalling, and/or one or more activators of cyclic AMP/PKA signaling; and a further embodiment provides a method for the differentiation of liver bud progenitors into hepatic progenitors by one or more inhibitors of TGFβ signalling and/or fibroblast growth factor (FGF) inhibitors and/or one or more Notch inhibitors. Another embodiment discloses the differentiation of hepatic progenitors into hepatocyte-like cells or perivenous hepatocyte-like cells by one or more of Notch inhibitors and/or activators of glucocorticoid signalling and/or one or more activators of insulin signalling and/or one or more of ascorbic acid signalling activators and/or additional factors. Methods and kits for maintaining LB in self renewal state, hepatocyte-like cells in perivenous or periportal state, as well as surface markers for LB and mid/hindgut (MHG) cells are also disclosed.
-
-
-
-
-
-
-
-
-